

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD., CELLTRION INC,
and BIOCON BIOLOGICS INC.

Petitioners,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Patent No. 11,253,572

Inter Partes Review No. IPR2023-00884¹

PATENT OWNER'S UPDATED MANDATORY NOTICES

¹ IPR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.

Patent Owner, Regeneron Pharmaceuticals, Inc., hereby files mandatory notices pursuant to 37 C.F.R. § 42.8(a)(3).

A. Real Party-in-Interest (37 C.F.R. § 42.8(b)(1)) – unchanged

The real party-in-interest is Regeneron Pharmaceuticals, Inc.

B. Related Matters (37 C.F.R. § 42.8(b)(2)) – unchanged

In accordance with the Office Patent Trial Practice Guide (77 Fed. Reg. 48756, at 48759-60 (Aug. 14, 2012)), Patent Owner identifies the following related matters:

U.S. Patent No. 11,253,572 was previously challenged in *Apotex Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2022-01524 (P.T.A.B.).

Related U.S. Patent No. 10,888,601 was challenged in *Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2022-01226 (P.T.A.B.), which was joined with IPR2023-00533 and IPR2023-00566. Patent Owner has appealed the Board's decision in IPR2022-01226 to the Federal Circuit in *Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.*, No. 24-1567 (Fed. Cir.). U.S. Patent No. 10,888,601 is also being challenged in *Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2023-00739 (P.T.A.B.) and in *Biocon Biologics Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2024-00201 (P.T.A.B.), which has been joined with IPR2023-00739.

Related U.S. Patent No. 10,130,681 was challenged in *Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2022-01225 (P.T.A.B.), which was joined with IPR2023-00532. Patent Owner has appealed the Board's decision in IPR2022-01225 to the Federal Circuit in *Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.*, No. 24-1564 (Fed. Cir.). U.S. Patent No. 10,130,681 is also being challenged in *Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2023-00442 (P.T.A.B.).

Related patents U.S. Patent Nos. 9,669,069 and 9,254,338 were challenged in *Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2021-00880 (P.T.A.B.) and in *Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2021-00881 (P.T.A.B.), respectively. IPR2021-000880 was joined with IPR2022-00257 and IPR2022-00301. IPR2021-00881 was joined with IPR2022-00258 and IPR2022-00298. Patent Owner has appealed the Board's decisions in those cases to the Federal Circuit, in *Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.*, No. 2023-1395 (Fed. Cir.) and *Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.*, No. 2023-1396 (Fed. Cir.), respectively.

U.S. Patent No. 11,253,572 and related patents have been asserted in *Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.*, No. 1:22-cv-

00061-TSK (N.D. W.Va.); *Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc.*, No. 1:23-cv-00089-TSK (N.D. W.Va.); *Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, Co., Ltd.*, No. 1:23-cv-00094-TSK (N.D. W.Va.); *Regeneron Pharmaceuticals, Inc. v. Formycon AG*, No. 1:23-cv-00097-TSK (N.D. W.Va.); *Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, Co., Ltd.*, No. 1:23-cv-00106-TSK (N.D. W.Va.); and *Regeneron Pharmaceuticals, Inc. v. Amgen, Inc.* 2:24-cv-00264 (C.D. Cal.).

Out of abundance of caution, Patent Owner further identifies *Chengdu Kanghong Biotechnology Co. v. Regeneron Pharms., Inc.*, Case No. PGR2021-00035 (P.T.A.B.) (proceeding terminated) regarding related U.S. Patent No. 10,828,345.

Out of an abundance of caution, Patent Owner further identifies *Apotex Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2023-00099 (P.T.A.B.) (proceeding terminated), regarding related U.S. Patent No. 10,857,205, which Regeneron disclaimed.

Patent Owner does not concede that the identified matters would affect, or be affected by, a decision in the present *Inter Partes* Review of U.S. Patent No. 11,253,572.

C. Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3)) – UPDATED

Lead Counsel	Backup Counsel
Adam R. Brausa Reg. No. 60,287 MORRISON & FOERSTER LLP 425 Market Street San Francisco, California 94105 Tel: (415) 268-6053 Fax: (415) 268-7522 ABrausa@mofo.com	Rebecca Weires Reg. No. 77,895 MORRISON & FOERSTER LLP 425 Market Street San Francisco, California 94105 Tel: (415) 268-6028 Fax: (415) 268-7522 RWeires@mofo.com
Backup Counsel	Backup Counsel
Kira A. Davis (<i>pro hac vice</i> , granted) MORRISON & FOERSTER LLP 707 Wilshire Blvd., Suite 6000 Los Angeles, California 90017 Tel: (213) 892-5654 Fax: (213) 892-5454 KiraDavis@mofo.com	Daralyn J. Durie (<i>pro hac vice</i> , granted) MORRISON & FOERSTER LLP 425 Market Street San Francisco, California 94105 Tel: (415) 268-6055 Fax: (415) 268-7522 DDurie@mofo.com
Backup Counsel (NEW)	Backup Counsel (NEW)
Matthew M. Wilk (<i>pro hac vice</i> , to be filed) Arnold & Porter Kaye Scholer LLP 250 West 55th Street New York, NY 10019-9710 Tel: (212) 836-7152 Fax: (212) 836-8689 matthew.wilk@arnoldporter.com	Jeremy Cobb (<i>pro hac vice</i> , to be filed) Arnold & Porter Kaye Scholer LLP 601 Massachusetts Ave, NW Washington, DC 20001-3743 Tel: (202) 942-6828 Fax: (202) 942-5999 jeremy.cobb@arnoldporter.com

Backup Counsel (NEW)
David A. Caine Reg. No. 52,683 Arnold & Porter Kaye Scholer LLP 3000 El Camino Real Five Palo Alto Square, Suite 500 Palo Alto, CA 94306-3807 Tel: (650) 319-4710 Fax: (650) 319-4700 david.caine@arnoldporter.com

D. Service Information (37 C.F.R. § 42.8(b)(4)) – unchanged

Please direct all correspondence regarding this proceeding to the counsel at the addresses listed above. Patent Owner also consents to electronic service by email to Regeneron-MoFo-IPR@mofo.com.

Dated: March 15, 2024

By: /Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105
Tel: (415) 268-6053
ABrausa@mofo.com

Counsel for Patent Owner

Certificate of Service (37 C.F.R. § 42.6(e)(4))

I hereby certify that the attached PATENT OWNER'S UPDATED
MANDATORY NOTICES was served as of the below date via email on the
Petitioners (by agreement) at the following correspondence address:

Raymond N. Nimrod (Reg. No. 31,987)
Matthew A. Traupman (Reg. No. 50,832)
Elliot Choi (*pro hac vice* granted)
Zachariah Summers (*pro hac vice* granted)
Sarah Cork (*pro hac vice* to be applied for)
Landon Andrew Smith (Reg. No. 79,248)
QUINN EMANUEL URQUHART
& SULLIVAN, LLP
51 Madison Ave., 22nd Floor
New York, NY 10010
General Tel: (212) 849-7000
Direct Tel: (212) 849-7322
Fax: (212) 849-7100
Email: raynimrod@quinnemanuel.com
Email: matthewtraupman@quinnemanuel.com
Email: elliotchoi@quinnemanuel.com
Email: zachsummers@quinnemanuel.com
Email: landonsmith@quinnemanuel.com
Email: qe-samsungbioepis@quinnemanuel.com

Paul J. Molino (Reg. No. 45,350)
William A. Rakoczy (*pro hac vice* to be filed)
Deanne M. Mazzochi (Reg. No. 50,158)
Heinz J. Salmen (*pro hac vice* to be filed)
Eric R. Hunt (*pro hac vice* to be filed)
Neil B. McLaughlin (Reg. No. 70,810)
Lauren M. Lesko (*pro hac vice* to be filed)
L. Scott Beall (Reg. No. 52,601)
Thomas H. Ehrich (Reg. No. 67,122)
Steven J. Birkos (Reg. No. 65,300)
Jake R. Ritthamel (*pro hac vice* to be filed)
Rakoczy Molino Mazzochi Siwik LLP

6 West Hubbard Street
Chicago, IL 60654
Telephone: (312) 527-2157
Facsimile: (312) 843-6260
Email: MYL_REG_IPR@rmmslegal.com

Lora Green (Reg. No. 43,541)
Yahn-Lin Chu (Reg. No. 75,946)
Robert Cerwinski (to be admitted *pro hac vice*, pending)
Aviv Zalcenstein (to be admitted *pro hac vice*, pending)
Brigid Morris (to be admitted *pro hac vice*, pending)
Gemini Law LLP
40 W 24th Street, Suite 6N
New York, NY 10010
Tel.: 917-915-8832
Email: lgreen@geminilaw.com
Email: fchu@geminilaw.com
Email: rcerwinski@geminilaw.com
Email: azalcenstein@geminilaw.com
Email: bmorris@geminilaw.com

Dated: March 15, 2024

/Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287